Association of Glucagon-Like Peptide-1 Receptor Agonist Use With Risk of Gallbladder and Biliary Diseases: A Systematic Review and Meta-analysis of Randomized Clinical Trials.
Quick Facts
What This Study Found
GLP-1 RA treatment was associated with a 37% increased risk of gallbladder or biliary diseases (RR, 1.37).
Key Numbers
How They Did This
The study conducted a systematic review and meta-analysis of 76 randomized clinical trials comparing GLP-1 RAs to placebo or non-GLP-1 RAs.
Why This Research Matters
Understanding the risks associated with GLP-1 receptor agonists is crucial for patient safety, especially as these drugs are increasingly used for weight loss and diabetes management.
What This Study Doesn't Tell Us
The study is limited to data from randomized trials, which may not capture all real-world scenarios and long-term effects.
Trust & Context
- Original Title:
- Association of Glucagon-Like Peptide-1 Receptor Agonist Use With Risk of Gallbladder and Biliary Diseases: A Systematic Review and Meta-analysis of Randomized Clinical Trials.
- Published In:
- JAMA internal medicine, 182(5), 513-519 (2022)
- Authors:
- He, Liyun, Wang, Jialu, Ping, Fan, Yang, Na, Huang, Jingyue, Li, Yuxiu, Xu, Lingling, Li, Wei, Zhang, Huabing
- Database ID:
- RPEP-06176
Evidence Hierarchy
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-06176APA
He, Liyun; Wang, Jialu; Ping, Fan; Yang, Na; Huang, Jingyue; Li, Yuxiu; Xu, Lingling; Li, Wei; Zhang, Huabing. (2022). Association of Glucagon-Like Peptide-1 Receptor Agonist Use With Risk of Gallbladder and Biliary Diseases: A Systematic Review and Meta-analysis of Randomized Clinical Trials.. JAMA internal medicine, 182(5), 513-519. https://doi.org/10.1001/jamainternmed.2022.0338
MLA
He, Liyun, et al. "Association of Glucagon-Like Peptide-1 Receptor Agonist Use With Risk of Gallbladder and Biliary Diseases: A Systematic Review and Meta-analysis of Randomized Clinical Trials.." JAMA internal medicine, 2022. https://doi.org/10.1001/jamainternmed.2022.0338
RethinkPeptides
RethinkPeptides Research Database. "Association of Glucagon-Like Peptide-1 Receptor Agonist Use ..." RPEP-06176. Retrieved from https://rethinkpeptides.com/research/he-2022-association-of-glucagonlike-peptide1
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.